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GENETICS, ETHICS AND EDUCATION
(Susan Bouregy, et al, eds., Cambridge Univ. Press: 2017)

Chapter 13: Development of the Personal Genomics Industry
By Jorge L. Contreras, J.D. and Vikrant G. Deshmukh, Ph.D., J.D.
Today, numerous commercial services offer genetic testing, genotyping and
genome sequencing services both to medical providers and directly to the public.
Twenty-five years ago, such offerings would have been unthinkable, both in terms of cost
and medical practice. This chapter describes the development of the personal genomics
industry and its evolving business models and goals.
Introduction
A recent study found that, between the beginning of the Human Genome Project
in 1990 and 2004, 470 different private firms in 25 countries began to offer products and
services based on genomic technology or data (Wiechers, Perin, & Cook-Deegan, 2013).
These commercial offerings included the sale of genome sequencing equipment and
reagents, the development of drugs and vaccines using genomic data
(pharmacogenomics), testing for disease susceptibility, and a host of data-driven
applications (Wiechers et al., 2013). Researchers at the Battelle Memorial Institute have
estimated (Battelle, 2013) that by 2012, more than 47,000 individuals in the U.S. alone
were employed by the genomics industry, which they divide into six primary sectors
(bioinformatics, testing, reagents, instrumentation, R&D and pharmacogenomics). Thus,
although the commercial genomics industry has existed for only twenty-five years, it is
large and complex, with widely varying product offerings, business models and
strategies.
In this chapter, we focus only on those segments of the commercial genomics
industry that offer products and services to end user consumers, either directly or through
intermediaries such as physicians, genetic counselors or testing laboratories, a sector that
we collectively refer to as “personal genomics” (Khoury et al., 2009). Our focus will
further be limited to those products and services that provide genetic or genomic
information to consumers, as opposed to drugs, vaccines or treatment regimens that may
have been discovered using genomic information, or the administration of which may be
influenced by a recipient’s genomic characteristics. But even limited thus, the field is
complex and multifaceted.
Genetics and Genomics
Each strand of human DNA consists of approximately 3.2 billion paired
nucleotide bases, the sum of which is referred to as the human “genome.” Some fraction
of these bases is organized into contiguous sub-units called “genes,” ranging in size from
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as few as a hundred to more than two million base pairs. It is currently estimated that
human DNA contains approximately 20,000 genes. Genes are responsible for the
inheritance of traits from one generation to the next and encode the many proteins
responsible for biochemical functions within the cell. Each human genome is
approximately 99.9% identical, and very small differences account for much of the
variability in human physical and physiological traits (Feuk, 2006; NHGRI, 2014a),
along with epigenetic variation (Issa, 2002).
While hypotheses regarding the existence of biochemical mechanisms for the
heredity of human traits have existed since the nineteenth century, it was not until
Watson and Crick’s landmark discovery of the structure of DNA in 1953 that modern
genetics was born. Throughout the 1960s and 1970s genetic studies became increasingly
sophisticated, until by the mid-1970s, technology had evolved to a point at which
researchers could begin to identify individual genes responsible for diseases such as
Cystic Fibrosis and Huntington’s disease (MacDonald, 1993; Rommens, 1989). Even so,
each of these discoveries took years of painstaking work and a measure of good luck to
achieve. In 1983 a revolutionary new process for determining the order of bases within a
DNA molecule emerged. This process, called the Polymerase Chain Reaction (PCR),
enabled researchers to unravel the genetic code of humans and many other organisms
more efficiently (Mullis, 1987), and earned its inventor, Kary Mullis at Cetus
Corporation, the Nobel Prize.
The advent of PCR technology soon gave rise to an ambitious plan to sequence
not only genes identified with specific diseases, but the entire human genome (Watson &
Jordan, 1989). The decision by the U.S. government to form an international consortium
to undertake this monumental project in the late 1980s signaled the birth of the field now
known as genomics, the study not of individual genes, but of the entire genome.
The Human Genome Project and Data-Driven Business Models
For most of the twentieth century, the bulk of genetic research was carried out at
academic institutions and government laboratories. The scale, sophistication and
speculative nature of such research generally made it unattractive to commercial
enterprises well into the first decade of the twenty-first century. The Human Genome
Project (HGP) was officially launched in 1990 as a joint project of the U.S. National
Institutes of Health (NIH) and the U.S. Department of Energy (DOE), with support from
the Wellcome Trust in the United Kingdom and funding agencies in the United Kingdom,
France, Germany and Japan.
The initial stages of the HGP were devoted to refining the instrumentation needed
to sequence the human genome and undertaking pilot sequencing projects on simpler
organisms such as the E. coli bacterium (Durham, 1997). By 1998, after the expenditure
of nearly $2 billion, the HGP prepared to begin work on the human genome. Then, in
May of that year, J. Craig Venter, a former NIH scientist, famously proclaimed that he,
with substantial commercial backing, would utilize state-of-the-art equipment, together
with much of the HGP’s publicly-released data, to sequence the entire human genome in
only three years, a full four years before the HGP was scheduled to complete its work
(Wade, 2000). Venter’s announcement sent a shock wave through the genomics
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community and led to a widely publicized “arms race” between his new company, Celera
Genomics, and the HGP (Roberts, 2001).
Ultimately, a truce was brokered by the journal Science (Jasny, 2013) and, in June
2000, Francis Collins, the leader of the HGP and Venter were invited to the White House
to announce jointly that a “first draft” of the human genome had been completed (Wade,
2000). In his remarks, President Clinton emphasized the role of commercial enterprises
in the new field of genomics, declaring that “[w]e must discover the function of these
genes and their protein products, and then we must rapidly convert that knowledge into
treatments that can lengthen and enrich lives. I want to emphasize that biotechnology
companies are absolutely essential in this endeavor” (Clinton, 2000).
Unlike the public HGP, Celera’s goal in sequencing the human genome was not to
release genomic data to the public, but to profit from licensing this data to pharmaceutical
and biotechnology companies. Like many companies, Celera sought to facilitate the
emerging pharmacogenomics industry, which, it was hoped, would develop new and
more effective drugs and vaccines guided by genomic information. Thus, while the
public HGP regularly uploaded its DNA sequence data to the public GenBank database
maintained by the U.S. National Library of Medicine, Celera made its data available
solely on its commercial web site. The company allowed scientists from non-profit and
academic institutions to access the data without charge, but required researchers who
wished to use the data for commercial purposes to enter into a license agreement
(Marshall, 2000).
Celera’s approach outraged much of the scientific community and led to a highly
publicized debate over private ownership of human genome data (Marshall, 2000). When
Celera and the HGP announced the completion of their first drafts of the human genome
in 2000, Celera committed that it would make its data broadly available, though it still
required payment by commercial users (Marshall, 2001b). Celera’s subscription-based
data business was ultimately unsuccessful and, in 2005, the company exited the business
and released its genomic data to GenBank (Kaiser, 2005). It is likely that Celera’s datadriven business failed, in large part, due to the competing public efforts that released
large quantities of similar, if not identical, data to the public.
In the 1990s Celera was just one of several firms that attempted to capitalize on
potentially profitable uses of genomic sequence data. Even before the completion of the
human genome project, firms including Incyte Pharmaceuticals in Palo Alto, California,
and Human Genome Sciences in Rockville, Maryland, were actively pursuing a business
strategy of patenting, and seeking to license, short gene sequences known as expressed
sequence tags (ESTs) and other genetic data (Marshall, 2001a). By the time the first EST
patent was issued to Incyte in 1998, that company alone had filed patent applications
claiming more than 1.2 million DNA sequence fragments (Murry, 1999). These early
efforts were eventually thwarted by a combination of factors including judicial and
administrative decisions limiting the patentability of ESTs (Demaine, 2002), as well as
earlier efforts to place large quantities of similar EST data into the public domain. The
most notable of these earlier efforts was the “Merck Gene Index,” a project led by
pharmaceutical giant Merck in collaboration with Lawrence Livermore National
Laboratory and Washington University (Contreras, 2011). By 1998, the Merck Gene
Index had released over 800,000 ESTs through GenBank, substantially limiting the
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ability of companies to license the same or similar data to the pharmaceutical industry in
a profitable manner.
A similar effort known as the SNP Consortium was conducted in conjunction with
the HGP by a group of pharmaceutical and information technology companies, with
additional support from the Wellcome Trust. The SNP Consortium sponsored research to
identify and map genetic markers referred to as “single nucleotide polymorphisms”
(SNPs), which it then released to the public domain (Holden, 2002; Contreras 2011).
SNPs are common genetic variations that occur throughout a person’s DNA, some of
which are important in the study of human health (Genetics Home Reference, 2014a).
The SNP consortium ultimately mapped 1.4 million SNPs, all of which were free from
patents and made publicly accessible without charge.
It is likely that public data release efforts by the HGP and associated private
sector projects such as the Merck Gene Index and the SNP Consortium limited the market
for general purpose genomic databases, though, as we discuss below, there may still be
substantial value in mutation databases associated with particular diseases.
The Genetic Testing Sector
The business models discussed in the section above were based on the private
generation or collection of large quantities of genomic data, with the goal that this data
then be licensed on a commercial basis to pharmaceutical and biotechnology companies
engaged in pharmacogenomics research. A different business model developed from
more narrowly-focused efforts to identify genetic mutations associated with particular
diseases. As of this writing, more than 37,000 different genetic tests are available from
1,600 laboratories and clinics in the U.S. for nearly 4,000 genetic disorders (GeneTests,
2014). The vast majority of these genetic tests are available to patients only through a
physician or clinical setting.
The first disease-specific genetic test was developed for Cystic Fibrosis, a
debilitating condition that affects approximately 30,000 children and adults in the United
States, and 70,000 worldwide (Cystic Fibrosis, 2014). A mutation in the CFTR gene that
is strongly correlated with Cystic Fibrosis was discovered in 1989 by teams at the
University of Michigan, Johns Hopkins University and the Hospital for Sick Children in
Montreal. The discovery was patented, but each of the institutions holding patent rights
elected to license its rights on a non-exclusive basis (meaning that the patent holder
permitted multiple laboratories to perform testing, rather than only a single laboratory)
(Chandrasekharan, Heaney, James, Conover, & Cook-Deegan, 2010). As a result, in
2009 sixty-three different labs in the United States performed testing for CFTR mutations
at relatively affordable prices (ibid.).
A different market structure developed with respect to tests in which controlling
patents were licensed on an exclusive basis. For example, Athena Diagnostics of
Marlborough, Massachusetts has exclusive rights to exploit patents covering genetic
diagnostic tests for mutations of several genes associated with hearing loss and
Alzheimer’s disease. In the case of the APOE gene, whose particular variants are
associated with late-onset Alzheimer’s disease, Athena holds an exclusive license from
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Duke University and has actively sought to prevent other laboratories from offering
testing based on this mutation (Skeehan, Heaney, & Cook-Deegan, 2010). One exception
arose in 2008, when Athena licensed a small company called Smart Genetics to offer
APOE testing directly to consumers via a mail-in kit in conjunction with telephone
consultation. But Smart Genetics discontinued its APOE testing program after only a few
months, apparently following the intervention of Duke University (Skeehan et al., 2010).
The best-known example of commercial genetic testing is probably that of Myriad
Genetics. Strong correlations between mutations in the BRCA1/2 genes and
breast/ovarian cancer in certain populations were identified in the early 1990s by research
groups at the University of Utah and the U.S. National Institutes of Environmental Health
Sciences (NIEHS) and two corporations: Myriad and Oncormed, Inc.. Myriad eventually
obtained control over the patents covering the most significant BRCA mutations and
elected not to license third parties to perform testing. As a result, by 2000 Myriad was
the only U.S. laboratory performing full BRCA testing, for which it charged
approximately $3,000. Controversy arose due to the cost of Myriad’s test and the fact
that many U.S. healthcare payors, including the federal Medicare system, declined to
cover BRCA testing costs in many cases. Myriad’s assertion of exclusive rights in the
BRCA testing market led a coalition of patients, advocacy groups, physicians and clinics
to mount a legal challenge against Myriad’s patents in 2009. The case led to a landmark
2013 decision by the U.S. Supreme Court invalidating all of the challenged patent claims
and establishing that DNA sequences occurring in the human body are not eligible for
patent protection in the U.S. (Ass'n for Molecular Pathology v. Myriad Genetics, Inc.,
2013).
Shortly after the Myriad ruling, a number of additional firms, including laboratory
giants Ambry Genetics and Laboratory Corporation of America, entered the market for
BRCA testing by offering tests at significantly lower price points than Myriad (Ambry,
2013; LabCorp, 2013). At this writing, Myriad is engaged in litigation seeking to enforce
a new set of patents against these and other firms.
The degree to which Myriad will impact patents held by Athena and other
diagnostic testing companies, and its overall effect on the genetic testing industry in the
U.S., is still unclear. Several commentators believe that single-gene patents of the type
held by Myriad and others would, in any event, be of little use to exclude competitors
from performing whole genome sequencing and other tests that involve more than the
isolation of single genes (Rai & Cook-Deegan, 2013).
Outside of the U.S., patents covering genetic testing appear to be on more solid
footing. The Australian Supreme Court, for example, recently upheld a number of
Myriad’s patents covering BRCA mutations ("Cancer Voices Australia v Myriad Inc
[2014] FCAFC," 2014). The crux of the dispute was whether isolated DNA including
complementary DNA (cDNA) was patent eligible. In holding both varieties of DNA to
be patentable, the Australian Court arrived at a different conclusion than the U.S.
Supreme Court, which had held that isolated DNA was not patent eligible because it was
a product of nature. In Europe, Myriad’s BRCA1 and BRCA2 patents were challenged
and substantially upheld by the European Patent Office (EPO). However, during
successive proceedings, the claims were reduced in scope from the entire BRCA1 gene
sequence to individual mutations, cloning vectors and host cells, and methods for
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detecting mutations in BRCA2 (Matthijs, Huys, Van Overwalle, & Stoppa-Lyonnet,
2013). The resulting claim scope in Europe is substantially narrower than in either the
U.S. or Australia.
Direct-to-Consumer (DTC) Genomics
Following the completion of the Human Genome Project, rapid advances in gene
sequencing technology coupled with a precipitous drop in the price of sequencing
equipment, led to the emergence of a new market: direct-to-consumer (DTC) genomic
testing. DTC genomics vendors offer services directly to the public, typically without the
involvement of a healthcare provider. These services typically involve the consumer’s
submission of a DNA sample (usually a saliva swab) to a designated facility, and the
vendor’s performance of one of three types of analysis: genotyping, exome sequencing or
whole genome sequencing (see Kornilov, this volume).
The process of scanning a genome for known genetic markers or SNPs is called
genotyping. Genotyping is typically performed by comparing a sample of human DNA
to known markers on a commercially available panel or “chip”. Vendors such as
Illumina currently offer genotyping panels that contain over one million known markers.
The presence or absence of the tested markers can support inferences about the subject’s
risk for certain diseases, ancestry and physiological characteristics.
While genotyping can offer a substantial amount of information to consumers,
even the largest million-marker chips contain only a tiny fraction (i.e. 0.03%) of the 3.2
billion base pairs comprising the full human genome. Sequencing the entire genome of an
individual (whole genome sequencing) is a much larger task. The HGP spent
approximately $3.8 billion over a decade to sequence the genomes of multiple individuals
to develop a common genomic profile for human species. The cost of genome
sequencing has dropped precipitously in the years since the completion of the HGP. For
years, the “holy grail” of genome sequencing has been the $1,000 genome: the ability to
sequence an entire human genome for a cost of only $1000 (Davies, 2010). The National
Human Genome Research Institute (NHGRI) tracks costs associated with whole genome
sequencing at centers that it funds, and most recently estimated that this cost had dropped
to between the $4,000 and $5,000 (Wetterstrand, 2014). And in 2014, Illumina
announced that it “broke the sound barrier” of human genomics by enabling the $1000
genome with a new sequencing platform (Illumina, 2014). Nevertheless, it is likely that
the $1000 genome still remains a few years away for the average consumer.
Meanwhile, companies like Gene by Gene offer a middle-road between
genotyping and whole genome sequencing in the form of exome sequencing, which
involves sequencing only those protein-coding fragments of an individual’s genome.
These 19,000 or so protein-coding regions represent about 1% of the entire human
genome (Ng et al., 2009), but can support medically valuable incidental/secondary
findings (Green et al., 2013). Thus, exome sequencing avoids the high cost of whole
genome sequencing, while offering more information than genotyping.
Ancestry Information
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Genetic ancestry testing (GAT) or genetic genealogy relies on an examination of
variations in DNA to infer where a person’s ancestors may have originated (Genetics
Home Reference, 2014b). GAT is based on the idea that closely related individuals,
families or populations share more genetic variations with one another. GAT can
complement traditional genealogical research by providing missing pieces of ancestry
information, but cannot itself provide detailed information about specific ancestors.
One of the first organizations to offer GAT to the public was the Genographic
Project, a collaboration between the National Geographic Society and IBM. The
Genographic Project began to distribute genetic testing kits in 2005 for a $99 charge
(Davies, 2010). The Project gave its participants information regarding their likely
ancestry, along with historical perspectives on the migration paths followed by ancient
peoples (Wells, 2005). The kits are still offered for $99, and at the time of this writing
over 688,000 individuals from more than 140 countries have participated in this project.
A number of additional commercial GAT tests are offered for approximately $99
by companies including 23andMe, Ancestry.com DNA and Family Tree DNA.
(23andMe, 2014a; Ancestry, 2014; Family Tree DNA, 2014).
Nutritional Genomics
The field of nutritional genomics pertains to interactions between genes and the
environment, particularly nutrients, chemicals, and other matter introduced into the body
as part of dietary food consumption (Dudley, 2013). For example, Familial
Hypercholesterolemia (FH), a condition characterized by severely elevated LDL
cholesterol and increased risk of coronary artery disease, can be traced to mutations in the
APOB, LDLR and PCSK9 genes. Individuals who carry these mutations are managed
medically by a combination of diet and lifestyle changes, along with pharmacotherapy
(Youngblom, 2014).
Some companies have tried to capitalize on public interest in nutritional genomics
through consumer testing products. For example, Evidence Based Nutrition (EBN) based
in Chula Vista, California, offers customers a “DNA Nutrition Action Plan” that “makes
nutritional and lifestyle recommendations based on an understanding of the individual’s
unique genetic profile” (Spicer, 2008). EBN primarily sells nutritional supplements.
Sciona, Inc., headquartered in Aurora, Colorado, offers the MyCellf test, which it
claims to be “designed to provide dietary and lifestyle recommendations gleaned from
individual genetic data” (Davies, 2010). Author Kevin Davies took the MyCellf test and
reported that Sciona recommended that he get more exercise, cut back on alcohol and
caffeine, and increase his daily intake of vegetables (ibid.). Predictably, claims such as
these from nutrigenetic testing firms have been criticized for being too generic at best,
and at times misleading (Kutz, 2006).
DTC and Health Information
While using genomic information to provide information about ancestry and
nutrition has commercial potential, these applications pale in comparison to the detection
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of health-related information hidden within the genomes of consumers. Home-based
genetic paternity testing, as well as genetic testing for specific health conditions, have
been available for years. Only with the increasing accessibility of genotyping and
genomic sequencing, however, have consumers had the opportunity to obtain large
quantities of data regarding their genomic make-up and its potential health implications.
In 1998, deCODE genetics, a Reykjavík, Iceland based biopharmaceutical
company, lobbied for and won exclusive rights to revamp Iceland’s national health record
system, which included records containing patient diagnoses, treatments, results,
complications, etc., as well as biospecimens, genotypes and genealogical records for the
entire nation (Chadwick, 1999). deCODE discovered several genes associated with
diseases in humans, and offered lab tests for various disease genotypes, in collaboration
with Hoffman-LaRoche, Merck, and others, although a majority of these tests were not
marketed to consumers.
In 2007, deCODE launched a web-based DTC genomics service called
deCODEme, which was the first commercial offering of its kind. For less than $1,000,
deCODE would analyze approximately 600,000 sites in a customer’s DNA having a
known influence on both common physical traits such as baldness, eye color and tonguerolling, as well as risk for certain diseases including diabetes and several cancers (Davies,
2010). DeCODE conceptualized its offering as an educational service rather than a
medical diagnostic, explaining “[w]e are not providing people with a genetic test. We are
only allowing them to compare their genomes to the genomes of those who in the
literature have been described as having a risk of a disease. We encourage people not to
make medical decisions on the basis of results of this, but we point people to the
possibility of taking results of this to their doctors…” (Davies, 2010).
In 2006, David Agus, an oncologist, and Dietrich Stephan, a neuroscientist,
founded Navigenics, Inc. Navigenics offered DTC tests for eighteen common illnesses
including diabetes, heart disease, obesity and certain cancers (Davies, 2010; Hall, 2007).
One of the distinguishing features of Navigenics’s approach was its heavy emphasis on
genetic counseling. Recognizing the complexity and sensitive nature of individual
genomic information, Navigenics required a “telephone consult” with one of its genetic
counselors before giving a customer full access to his or her DTC testing results.
Customers could also download their raw genomic data after signing a waiver.
The best-known purveyor of DTC genomic testing today is probably 23andMe, a
California-based company founded by Linda Avey, Paul Cusenza and Anne Wojcicki in
2006 (23andMe, 2014a). In November 2007, 23andMe joined deCODE and Navigenics
in offering the public DTC testing that included ancestry and health information
(Hanahan, 2007). Wojciki, the spouse of Google co-founder Sergey Brin, explained,
“23andMe is designed to provide our customers with scientifically accurate, high-quality
information about their own genetic code in a format that is easy to understand and use.”
23andMe’s bold approach and knack for publicity quickly grabbed the public
imagination, and Time Magazine named it the 2008 ‘Invention of the Year’ (TIME
Magazine, 2008). 23andMe has also attracted investment from other pharmaceutical and
biotechnology companies since its founding, and recently announced a $60 million deal
with biotech giant Genentech. A significant aspect of this investment will give
Genentech access to the 23andMe database containing genotypic records of over 800,000
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customers (Herper, 2015). In February 2015, the U.S. Food and Drug Administration
(FDA) allowed 23andMe to market the first DTC genetic carrier test for Bloom syndrome
(U.S. Food and Drug Administration, 2015), a rare genetic disorder characterized by
short stature and increased predisposition to cancer.
Even independently of 23andMe, Google’s interest in the field of genomics is not
to be underestimated. In February 2014, the Internet giant launched Google Genomics, a
web-based application for importing, storing, searching, analyzing and sharing individual
genomic data (Gruber, 2014). Harvard professor George Church predicts that Google’s
data mining software will open “huge new markets in wellness and precision medicine
(ibid.).”
Alongside these purveyors of broad spectrum DTC genomic information are
numerous smaller firms that offer genotyping for specific non-disease traits. Among
these is Richmond, Virginia based American International Biotechnology, which offers a
$200 test kit that “provides athletes and parents of young sports competitors a wealth of
information about their athletic strengths” (AIBioTech, 2011). Some in the scientific
community have questioned the validity of the conclusions that can be drawn from such
information, and have criticized the marketing approach taken by AIBioTech and others
(Collier, 2012).
Comparing DTC Offerings
With at least three major DTC personal genomics options available to consumers
by the late 2000s, it became important to clarify how these services differed from one
another. Whereas 23andMe took a self-service approach in providing the consumer with
large quantities of easy-to-use information, Navigenics and deCODE preferred that
consumers interact with genetic counselors to interpret their results. And while 23andMe
offered more information on complex traits, deCODE offered greater contextual
information for data relating to ancestry (Davies, 2010).
The similarities and differences among DTC genomics offerings also became the
object of scientific study. One such study found over 99.6% concordance in the SNP
genotypes provided by deCODE, 23andMe and Navigenics (most likely because they all
used the same commercial genotyping technology), but noted large variations in the
analysis of risks reported by these companies (Imai, Kricka, & Fortina, 2011). For
example, one study found that the relative risks for rheumatoid arthritis that the
companies reported ranged from 0.9 to 1.85, i.e. from having a protective effect to having
a deleterious effect (ibid.). Similar findings were observed in other studies, and the
differences were attributed, among other things, to the methods used in characterizing the
underlying populations (Kalf et al., 2014).
While academic studies have provided a scientific comparison of DTC services,
members of the media have also reported their experiences with DTC testing (Dickinson,
2008). Journalist Boonsri Dickinson, for example, compared her DTC test results from all
three companies and received surprisingly divergent results. Having both Asian and
European ancestry, she discovered that the risk information provided by the test vendors
varied widely depending on whether she identified herself as belonging to one ethnic
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group or the other. Such critiques have cast increasing doubt on the usefulness and
informative value of many DTC genomic services.
Whole Genome Sequencing for All?
Around the time that deCODE, 23andMe, and Navigenics were marketing DTC
genomic tests based on known markers, others, like Harvard professor George M.
Church, ventured in a different direction. Church was one of the first individuals to have
his entire genome sequenced and joined other notable figures such as James Watson in
releasing his genomic data to the public. Church founded Knome Inc. in 2007 to offer
whole genome sequencing services to the general public, “on the recognition that the
rapidly falling price of whole genome sequencing would create substantial market need
for whole genome interpretation technologies and services” (Knome, 2014). Today, that
vision has largely been realized; indeed, when Knome first offered whole genome
sequencing, it cost a hefty $350,000, whereas more recent cost estimates are in the $6,000
range (Eisenberg, 2013).
Other notable companies in the whole genome sequencing arena included Helicos
Biosciences and Complete Genomics. Helicos was founded in 2003 by Stephen Quake
from the California Institute of Technology, and Stanley Lapidus and Noubar Afeyan of
Flagship Ventures. Helicos specialized in a novel technique known as Single Molecule
Sequencing, which allowed the sequencing of a single DNA molecule without the need
for PCR, and offered an advantage over second-generation sequencing techniques at the
time (Thompson & Milos, 2011).
Complete Genomics was founded by Clifford Reid and Radoje (Rade) Drmanac
in 2006. In 2009 the company began to offer whole genome sequencing services not to
consumers, but to pharmaceutical and biotechnology companies and academic medical
centers at a cost of approximately $5,000 per genome (Lauerman, 2009). While Knome
and Complete Genomics continue to offer whole genome sequencing services as of this
writing, Helicos filed for bankruptcy in 2012.
The potential of DTC whole genome sequencing is significant. What cost the
HGP $3.8 billion to produce over ten years could soon be available to every man, woman
and child for less than $1,000 through a mail-in kit. The greatest challenge of DTC
whole genome sequencing is how to interpret the vast quantity of genomic data that will
be delivered to consumers. Modern science has only scratched the surface of
understanding the myriad functions of the 3.2 billion base pairs that constitute the human
genome. It will likely be many years before scientific understanding catches up with the
technical ability to generate whole genome sequence data.
Market Shake-out for DTC Vendors
The financial crisis of 2008 put an enormous strain on many industries, and
several DTC genomics providers went out of business. In November 2009, two years
after initially offering its DTC service, deCODE filed for bankruptcy. deCODE got a
fresh start in 2012, when it was acquired by biotech giant Amgen (Amgen, 2012). It is
not clear, however, whether Amgen will restart deCODE’s DTC genomics service, or
simply use the Icelandic company’s genetic resources and database to support its existing
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drug discovery and development businesses. In 2012, Navigenics also ceased to offer
DTC genomic services after being acquired by Life Technologies, a subsidiary of
equipment manufacturer Thermo Fisher Scientific. Whereas both deCODE and
Navigenics struggled, 23andMe has flourished, attracting over $100 million in investment
from the likes of Google, Johnson and Johnson, and Genentech, and major private
investors such as Google co-founder Sergey Brin and Digital Sky Technologies cofounder Yuri Milner (CrunchBase, 2014).
Governmental Scrutiny of DTC Testing
In 2004, the American College of Medical Genetics issued a statement that
“genetic testing should be provided to the public only through the services of an
appropriately qualified health care professional,” warning that “the self-ordering of
genetic tests by patients over the telephone or Internet [could result in harms including]
inappropriate test utilization, misinterpretation of test results, lack of necessary followup, and other adverse consequences” (ACMG, 2004). This perspective has shaped the
policy debate over DTC genomic services in the United States, and has led to significant
intervention by state legislatures and federal agencies over the DTC genomics industry.
In the United States, state governments are generally responsible for regulating
consumer health and safety, as well as the practice of medicine and licensure of
healthcare providers within their borders. Depending on the state, laws and regulations
may either expressly permit genomic DTC testing, ban such services outright, impose
partial regulations or remain silent on the issue (Dick, 2012; Berman, 2007). Illustrating
this range of regulatory regimes, Virginia explicitly allows direct reporting of DTC
genomic results to individuals, California and New York require physician authorization,
and Colorado and Utah classify DTC genomic testing outside the practice of medicine
and thus beyond state licensure regulation (Dick, 2012).
In 2008, both California and New York began to require medical licensing for
DTC genomics vendors and sent cease and desist letters prohibiting further sales to
consumers without medical oversight (Langreth, 2008; Magnus, Cho, & Cook-Deegan,
2009; Pollack, 2008). The targeted DTC companies objected, arguing that patients had a
right to receive their genetic information, that genetic testing is not diagnostic or medical
in nature, and that patients deserved direct access to testing without a physician
intermediary (Magnus et al., 2009). Nevertheless, most DTC companies eventually
complied with state demands and stopped accepting DNA samples from New York and
California (Pollack, 2008). 23andMe, however, took a creative approach, still shipping
kits to consumers in New York, but requiring them to “affirm under penalty of law that
the sample for the saliva kit has not been collected in or mailed from the state of New
York” (23andMe, 2014b). On the other hand, in 2010, Navigenics became one of the
first DTC genomics companies to obtain a New York Clinical Laboratory Permit
(Sweeney, 2010).
The U.S. federal government has also shown an interest in the activities of DTC
genomics vendors. In 2006 the U.S. Government Accountability Office (GAO) launched
an investigation of the practices of several DTC companies, and concluded in a
subsequent investigation that they provided “medically unproven disease predictions” (G.
Kutz, 2010). GAO’s investigation involved the purchase of DTC tests by a number of
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fictitious consumers. These test subjects received disease and risk predictions that varied
across four DTC companies for the same DNA samples, and contradicted known family
history and other traits in the DNA donors.
DTC genetic testing is subject to the jurisdiction of at least three separate Federal
regulatory agencies: the Federal Trade Commission (FTC), the Centers for Medicare and
Medicaid Services (CMS), and the Food and Drug Administration (FDA)(NHGRI,
2014b).
The FTC regulates consumer protection and polices false and misleading
advertising under the Federal Trade Commission Act. There have been numerous
critiques of consumer DTC genomics advertising, pointing to its potential distortion of
DTC testings’ risks and benefits, its limited educational value and its potential for
disseminating misinformation to the public (Gollust, Hull and Wilfond, 2002). As a
result, the FTC has scrutinized DTC genomics advertising and has issued a consumer
advisory on its website about DTC genetic tests, alongside other cautionary articles about
“miracle health claims” and “cancer treatment scams” (Federal Trade Commission,
2014).
CMS regulates clinical laboratory testing (excluding research) throughout the
U.S. under the Clinical Laboratory Improvement Amendments (CLIA) of 1988, which
covers the educational requirements, quality control and proficiency testing of individual
labs. In order to offer medical tests to the public and return results to consumers,
laboratories performing DTC genomic testing must have an appropriate CLIA certificate
(CMS, 2014).
Separately from CMS’s regulation of clinical laboratories, the FDA regulates
medical devices marketed in the U.S. under the Medical Devices Amendments to the
Federal Food, Drug and Cosmetic Act. FDA’s broad oversight of medical devices has
been argued to extend to laboratory-developed tests and test kits, as well as related
software (Javitt & Carner, 2014).
In 2009, the FDA, which had become increasingly concerned about the
distribution of genomic diagnostic information by unregulated DTC vendors, began to
seek more information regarding DTC practices and tests. The major DTC genomics
vendors largely sidestepped the FDA’s inquiries, and matters came to a head in the
summer of 2010, when the FDA issued warning letters to several vendors including
23andMe, Navigenics, and deCODE (U.S. Food and Drug Administration, 2010).
According to the FDA, the kits and services offered by these vendors fell under the
Medical Devices Amendments, and these firms had neither filed for premarket approval,
nor notified the agency of their intent to commercially distribute the respective devices.
On this basis, the FDA ordered these companies to discontinue marketing DTC genomic
services until they received marketing authorization from the FDA, and to provide
documentation about specific corrective actions they had undertaken to address these
issues (ibid.).
As a result of the FDA’s actions, in December 2013, 23andMe announced that it
was discontinuing the ‘23andMe Health’ personal genomics service, which had provided
consumers with health-related interpretive information along with the results of its
genotyping analysis, pending an FDA regulatory review (Afarian, 2013). 23andMe

Contreras and Deshmukh

Page 13

switched instead to providing its customers with raw SNP data (i.e., the actual genotypic
test results indicating the presence of particular SNPs at particular locations along the
genome), along with ancestry information. Other DTC companies that offered similar
tests followed suit, limiting their offerings to raw SNP data and leaving consumers to
perform their own interpretations.
Despite the current unavailability of interpretive or health information from DTC
vendors, consumers who obtain SNP and other raw genomic data about themselves are
not without options. Free software tools such as Promethease (Promethease, 2014) can
generate personal genomics reports using raw sequence data based on publicly available
scientific literature in the public SNPedia (Cariaso & Lennon, 2012; SNPedia, 2014).
Promethease can import data directly from the reports offered by vendors such as
23andMe, and can also decipher raw data files that most DTC vendors provide to
consumers. The actual process involves matching raw SNP data with known SNPs in
SNPedia, and using that knowledge base to generate meaningful interpretation. Other
websites such as interpretome.com (Karczewski, 2012), livewello.com (Livewello, 2015),
and geneticgenie.org (Genetic Genie, 2015) also offer “interpretation-only” services for
DTC tests similar to Promethease. Due to the rapid pace of discovery and the relative
newness of these services, there is no gold standard. Nevertheless, one recent study found
Promethease results to be among the most detailed, although not as user-friendly as the
services originally offered by 23andMe (Regalado, 2014). Ultimately, the accuracy of
these tools is only as good as the underlying data sources. SNPedia, for instance, has at
least four levels of data curation, three of which are directly performed on the database
itself, whereas an additional fourth level of review is dedicated to the content used by
Promethease, and helps screen errors in original research in the original data-sources
(Cariaso & Lennon, 2012).
Personal Genomics outside the U.S.
Though, with the exception of deCODE in Iceland, the personal genomics
initiatives of U.S. firms have received most of the attention from the Western press, such
efforts are not limited to the U.S. market. Regulators around the world have weighed the
benefits and risks of genetic testing, including DTC, for several years, and legal
developments in Europe bear striking similarities to those in the United States. In 2008,
following the approval of protocols related to genetic testing by the Committee of
Ministers of the Council of Europe, some speculated that Europe might move toward
banning DTC testing altogether (Borry, 2008). In 2009, Germany enacted legislation that
effectively banned DTC genomic services by requiring that genetic tests be carried out
exclusively by a physician following informed patient consent (The Associated Press,
2009). France, Portugal and Switzerland have similar legislation restricting DTC
genomics, while the Netherlands only has limited restrictions on genetic tests for
detecting “incurable diseases” (Borry et al., 2012). The United Kingdom and Belgium
currently have no specific restrictions on DTC genomic testing (ibid.).
In the EU, DTC testing is currently covered by European Directive 98/79, which
proposes objectives, but is not directly binding on member states, many of which have
national legislation that covers these tests (Kalokairinou, 2014). However, a new
proposed regulation, if adopted by the EU, would be binding on member states. The
regulation proposes a risk-classification system for medical devices including DTC tests.
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It further provides that agencies must evaluate claims before such tests could be marketed
(ibid). Finally, the regulation would also provide that only medical professionals can
order these tests. Such a change in regulatory posture could effectively ban DTC in
Europe (ibid.).
Like the U.S., China has seen the emergence of a significant personal genomics
industry, offering consumers both genetic testing for common health risks (especially
neonatal screens), as well as more comprehensive genomic data (Jia, 2014). It has been
reported that many Chinese hospitals routinely offer genomic sequencing services to
healthy patients during check-ups (ibid.) The increasing popularity of personal genomic
services in China has led Chinese regulators to take notice, and it is likely that greater
scrutiny and regulation of the personal genomics market in China will soon arrive.
Despite these moves toward greater regulation of DTC testing, there have also
been calls for scaling back the initial precautionary approach taken by regulators in light
of newer studies, which show that many of the public health concerns over DTC have not
materialized (Vayena, 2013). In a recent study, most participants in multiplex genetic
susceptibility testing recalled their results correctly, did not interpret results in an overly
deterministic way, and appreciated that genetics and behavior both contribute to disease
risk (Kaphingst, 2012). In another study, subjects who underwent DTC testing exhibited
no measurable short-term changes in psychological health, diet and exercise behavior, or
use of screening tests (Bloss, 2011).
While commercial genomics itself knows no boundaries, and consumers from
different parts of the world could potentially send their DNA samples to vendors based in
other countries, until regulatory frameworks around the world catch up with the
technology, the industry may need to self-regulate in the consumers’ interest (Gurwitz &
Bregman-Eschet, 2009). Whereas many laboratory-developed tests would arguably fall
within the definition of a “device” that is subject to FDA regulation, there is a lack of
data to support pre-market clearance, and the FDA cannot control off-label uses of these
tests (McGuire, 2010). Moreover, many DTC tests provide predictive and long-term
information, whereas post-market surveillance may provide a better long-term strategy as
long all tests are analytically valid, and all clinical claims are accurate and substantiated
(ibid.).
Additionally, typical DTC contracts include numerous legal disclaimers and
limitations of liability (Phillips, 2015). Most consumers lack the training to interpret
these terms, or do not invest the time to do so. While regulation may be necessary to
protect consumer interests, in the short-term DTC companies can also improve the
readability of their contracts and privacy policies to enhance consumer understanding and
the consent process (ibid.). The lessons learned in early adopter countries like the United
States and several European nations are pertinent to consumers and companies around the
world due to their impact on the availability and demand for DTC and other forms of
genetic testing.
Conclusion
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Over the past twenty-five years, the increasing speed and decreasing cost of
genotyping and genome sequencing have led to the emergence of new business models
based on providing genetic information directly to the public. Genetic tests for individual
diseases are widely available today in many developed countries at moderate cost, and
are covered by many national and private insurance plans. DTC genomic testing offered
by 23andMe and similar providers has increased in popularity, but the medical value of
these services remains to be proven. Such services also face increasing governmental
scrutiny and regulation, either as healthcare providers or diagnostic device vendors,
making their future uncertain. Whole genome sequencing, which will soon be broadly
affordable, offers consumers a wealth of information, but much of the information that is
delivered is not likely to be understood for years. As such, the value of whole genome
sequencing, as opposed to genotyping for known disease risks, remains questionable.
The global market for personal genomic products and services is likely to evolve
rapidly over the next five to ten years. DTC companies have responded to changes in the
regulatory environment by emphasizing services like ancestry information to maintain
their primary revenue streams. Other companies have begun to offer interpretation-only
services for personal genomics, which have not yet received the same level of scrutiny as
similar services previously offered by DTC companies. Finally, in addition to the
primary market for these products, collaborations between DTC and major biotechnology
and pharmaceutical companies could create secondary markets and augment their
primary business models along the lines of 23andMe. It is not clear which of today’s
players, if any, will remain active in the future, or whether new players will enter the
market from other sectors such as computing, information technology and online
services, and whether early U.S. players will remain dominant in the face of market entry
by competitors in China and elsewhere. What is certain, however, is that the amount of
genomic information available to the general public will continue to increase rapidly, and
novel legal, ethical and economic solutions will need to keep pace with this remarkable
technological growth.
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